Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
The study population consisted of patients with a documented history of episodic (4 - 14 baseline migraine days) or chronic migraine (≥15 baseline headache days), who had been successfully randomized to clinical trial CAMG334ADE01.~Key inclusion Criteria:~* Signed informed consent must be obtained prior to participation in the study~* Patient is capable of understanding the nature, significance and implications of the clinical trial.~* Adults ≥18 years of age upon entry into screening~Key exclusion Criteria:~* Use of a prophylactic migraine medication within five plasma clearance half-lives, or a device or procedure within one month prior to the start of the Open-label Treatment Epoch. This exclusion criteria does not apply to erenumab or topiramate administered within clinical trial CAMG334ADE01~* Any prior exposure to (investigational) prophylactic migraine products targeting the CGRP pathway, other than erenumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 67 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): Erenumab dose could be adjusted from 70 mg to 140 mg or vice versa at the discretion of the physician at any scheduled study visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).